Home / Conditions / Guillain-barré Syndrome

Guillain-barré Syndrome: when insurers say no, reviewers often say yes

In 13 published external-review decisions involving guillain-barré syndrome, independent physician reviewers overturned the insurer’s denial 15.4% of the time.

Published decisions
13
2001–2026
Overturned
15.4%
2 denials reversed
Typical time to a decision
11 days
Most land between 5 and 18 days
Handled as urgent
53.8%
Expedited when a delay would cause harm
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.

Where the denial was overturned

An enrollee has requested reimbursement for air ambulance services provided. Findings: The physician reviewer found that the air ambulance services provided was medically necessary for treatment of the patient’s medical condition. GBS is an acute progressive sensory-motor polyneuropathy. It is an autoimmune condition which if untreated can progress to respiratory failure, and can be fatal. It is standard of care for an acute GBS patient to have access to neurology and critical care expertise. IVIG is standard of care for GBS. In this case, air ambulance services from Arcata to Sacramento is estimated to be less than two hours. In addition, the hospital is an estimated 3-4 hours by ground transport lists two neurologists within a 10 mile radius.
Medical Necessity · 2016 · IMR MN16-23786
The spouse of a 59-year-old male enrollee has requested transfer to a facility with a higher level of care for the treatment of the enrollee’s multiple medical conditions including Guillain-Barre Syndrome. Findings: The physician reviewer found that this patient has had a severe paralytic illness, consistent with Guillain Barre Syndrome (GBS). The prolonged nature of his symptoms, along with observed atrophy, suggests axonal involvement as is seen in the acute axonal variant of GBS. CIDP is a chronic form of demyelinative neuropathy, reaching a nadir in more than eight weeks. IVIG can be beneficial for GBS, but does not always result in improvement. Plasmapheresis has been shown beneficial for GBS when given early in the illness. As with other inflammatory neuropathies, CIDP is treated with immunosuppressants with variable levels of evidence for the efficacy of each.
Medical Necessity · 2009 · IMR MN09-9564

Where the denial was upheld

Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement for SNF services. Admission to a SNF is appropriate for patients with conditions that require observation, evaluation of treatment plans, and updating of orders by a physician along with constantly available skilled nursing services. Skilled nursing services may include wound management, tracheostomy care, bowel and bladder training, tube feeding, and the administration of intravenous (IV) medications or medications that cannot be self-administered safely. Skilled nursing observation may include regular monitoring of vital signs, skin in the setting of wounds, and intake and output. Patients typically also benefit from skilled therapy services such as physical, occupational, and speech therapies due to physical limitations, a decline in function, or impaired cognition and communication.
Medical Necessity · 2024 · IMR MN24-41034
Nature of Statutory Criteria/Case Summary: A 56-year-old male enrollee has requested reimbursement for long-term acute care inpatient stay for treatment of Guillain-Barre syndrome and West Nile virus. Findings: The physician reviewer found that the submitted documentation fails to demonstrate the medical necessity of the services at issue. Guillain-Barre syndrome generally has a favorable natural course and relatively good prognosis. There are treatment options such as intravenous immunoglobulin and plasma exchange that have demonstrated to be effective treatments for this condition. However, despite the generally good prognosis and available therapeutic options, some patients continue to have significant functional impairments at six months or longer following the onset of symptoms.
Medical Necessity · 2017 · IMR MN17-24387

Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.

How to use this in your appeal

These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for guillain-barré syndrome was denied, the published record says the denial is worth fighting.

SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY

Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.

Fighting a denial for guillain-barré syndrome? 15.4% won.

Explain my denial — freeStart my appeal · $39